Letters to the Editor

Adalimumab for refractory idiopathic scleritis in children

C. Gaggiano¹, M. Tarsia², G.M. Tosi³, S. Grosso⁴, B. Frediani⁵, L. Cantarini⁶, C. Fabiani⁷

Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, and Clinical Paediatrics, Department of Molecular Medicine and Development, University of Siena, Italy.
Clinical Paediatrics, Department of Molecular Medicine and Development, University of Siena, Italy.
Ophthalmology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
Clinical Paediatrics, Department of Molecular Medicine and Development, University of Siena, Italy.
Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. cantariniluca@hotmail.com
Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, and Ophthalmology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

CER14381
2022 Vol.40, N°7
PI 1447, PF 1448
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 35238748 [PubMed]

Received: 03/01/2021
Accepted : 19/04/2021
In Press: 01/02/2022
Published: 04/07/2022